gensaic

Decoding the language of delivery @labcentral

[gensaic @GensaicBio]

Together, we aim to unlock the next generation of cardiometabolic therapies by combining our expertise in tissue-selective delivery and computational protein design with Novo Nordisk’s deep therapeutic knowledge and drug development experience.

[gensaic @GensaicBio]

We are excited to announce that Gensaic has entered into a partnership with @novonordisk!

Read more about our partnership here:
https://t.co/VoEcAEh4Z5

[Cormac Sheridan @Cormac_Sheridan]

Why gene therapies must go virus-free: Why is #genetherapy so costly when #mRNA #vaccines are so cheap? Non-viral delivery of mRNA to the cytoplasm is now routine; non-viral delivery of DNA to the nucleus isn't - but may soon be. Just out in @NatureBiotech https://t.co/Oniru5135e

[gensaic @GensaicBio]

Catch our team at #ASGCT23! We’re looking forward to learning and discussing the newest developments in gene therapy.

[Jeremy Levin @jmaxlevin]

Neuroscience is on the cusp of a paradigm shift in the delivery of genetic materials to the brain. @GensaicBio has pioneered a world-leading delivery platform, and @OvidRx was proud to help kick-start this critical step in healing diseases of the brain. https://t.co/8AodusifUM

[Cystic Fibrosis Foundation @CF_Foundation]

We are investing up to $3.5M in Gensaic Inc. to conduct preclinical research to develop a new approach to deliver a gene therapy to the lung cells of people with #cysticfibrosis.
https://t.co/Er8ivtdAm3

[gensaic @GensaicBio]

Gensaic has received funding from the @CF_Foundation to help us develop our gene therapy platform for CF! We are highly appreciative and excited about this opportunity to work on this severe disease.
https://t.co/pCrk8wWlKN

[LabCentral @LabCentral]

And the results are in! Congratulations to @futurefieldsHQ and @GensaicBio on securing this year’s @novonordisk Golden Ticket! #WhereBiotechBegins

[gensaic @GensaicBio]

Announcing a strategic collaboration with Ovid Therapeutics (@OvidRx) to develop our phage-derived gene delivery platform for rare genetic CNS diseases. The collaboration entails up to 3 therapeutic programs and completes a $5M equity investment.
https://t.co/gjGMWqj3Bw

[gensaic @GensaicBio]

Catch our team members @simontphd and Maggie Lejeune at #phagefutures today and tomorrow!

[gensaic @GensaicBio]

The inherent modularity of the phage platform offers the possibility of greatly expanding the repertoire of targeting and DNA cargos. Learn more at https://t.co/b1GdeDwjuw

[gensaic @GensaicBio]

Our co-founder Amin Hajitou just published a paper using engineered phage-derived particles (PDPs) for cancer immunotherapy: https://t.co/x6tzuEKcMM .../

[gensaic @GensaicBio]

These engineered PDPs carrying IL-12, IL-15, and TNFa showed effective targeted delivery to tumors in vivo, followed by reductions in tumor size and increased survival.../

[gensaic @GensaicBio]

We're hiring a research associate to join our team! Please apply at the link: https://t.co/EPt26zdaE6

[gensaic @GensaicBio]

Officially launching our new name and website: https://t.co/b1GdeDwjuw